A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401-Reference-Cited by-同舟云学术

A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401

Published:2011-02 Issue: Volume: Page:
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Nogami Naoyuki,Hotta Katsuyuki,Kuyama Shoichi,Kiura Katsuyuki,Takigawa Nagio,Chikamori Kenichi,Shibayama Takuo,Kishino Daizo,Hosokawa Shinobu,Tamaoki Akihiko,Harita Shingo,Tabata Masahiro,Ueoka Hiroshi,Shinkai Tetsu,Tanimoto Mitsune

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer;Noda;N Engl J Med,2002

2. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer;Hanna;J Clin Oncol,2006

3. Small cell lung cancer;Krug,2008

4. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results;Oze;PLoS One,2009

5. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer;Ettinger;Semin Oncol,2001

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment;Diagnostics;2024-07-19

2. Topotecan inhibits metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition;European Journal of Medicinal Chemistry Reports;2022-08

3. Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future;Translational Lung Cancer Research;2020-04

4. Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133);Clinical Lung Cancer;2019-11

5. Second-line treatments of small-cell lung cancers;Expert Review of Anticancer Therapy;2017-09-08